Search

Your search keyword '"Ghione, S."' showing total 604 results
Start Over Author "Ghione, S."
604 results on '"Ghione, S."'

9. Platelet Membrane Glycoprofiling in a PMM2-CDG Patient

Author

Papazoglu, G.M., primary, Ruiz, S.M. Silvera, additional, Salinas, R., additional, Pereira, M.I., additional, Cubilla, M.A., additional, Pesaola, F., additional, Ghione, S., additional, Ramadán, N., additional, Martinez-Duncker, I., additional, and Asteggiano, C.G., additional

Published
2021
Full Text
View/download PDF

12. The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy

Author

Armuzzi, A. (ORCID:0000-0003-1572-0118), Fiorino, G., Variola, A., Manetti, N., Fries, W., Orlando, A., Maconi, G., Bossa, F., Cappello, M., Biancone, L., Cantoro, L., Costa, F., D'Inca, R., Lionetti, P., Principi, M., Castiglione, F., Annunziata, M. L., Di Sabatino, A., Di Girolamo, M., Terpin, M. M., Cortelezzi, C. C., Saibeni, S., Amato, A., Ardizzone, S., Guidi, L. (ORCID:0000-0003-3320-7094), Danese, S., Massella, A., Ventra, A., Rizzuto, G., Massari, A., Perri, F., Annese, V., Saettone, S., Tari, R., Petruzzellis, C., Meucci, G., Imperiali, G., Guglielmi, F. W., Mazzuoli, S., Caserta, L., Parodi, M. C., Colli, A., Ronchetti, A., Pugliese, D., Geccherle, A., Rogai, F., Milani, S., Renna, S., Cassinotti, A., Andriulli, A., Martino, G., Scrivo, B., Troncone, E., Kohn, A., Bertani, L., Lorenzon, G., Ghione, S., Nardone, O., Vecchi, M., Bertani, A., Bosani, M. A., Bezzio, C., Salerno, R., Armuzzi, A. (ORCID:0000-0003-1572-0118), Fiorino, G., Variola, A., Manetti, N., Fries, W., Orlando, A., Maconi, G., Bossa, F., Cappello, M., Biancone, L., Cantoro, L., Costa, F., D'Inca, R., Lionetti, P., Principi, M., Castiglione, F., Annunziata, M. L., Di Sabatino, A., Di Girolamo, M., Terpin, M. M., Cortelezzi, C. C., Saibeni, S., Amato, A., Ardizzone, S., Guidi, L. (ORCID:0000-0003-3320-7094), Danese, S., Massella, A., Ventra, A., Rizzuto, G., Massari, A., Perri, F., Annese, V., Saettone, S., Tari, R., Petruzzellis, C., Meucci, G., Imperiali, G., Guglielmi, F. W., Mazzuoli, S., Caserta, L., Parodi, M. C., Colli, A., Ronchetti, A., Pugliese, D., Geccherle, A., Rogai, F., Milani, S., Renna, S., Cassinotti, A., Andriulli, A., Martino, G., Scrivo, B., Troncone, E., Kohn, A., Bertani, L., Lorenzon, G., Ghione, S., Nardone, O., Vecchi, M., Bertani, A., Bosani, M. A., Bezzio, C., and Salerno, R.

Abstract

Background: We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. Methods: A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. Results: Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naïve to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One hundred fifty-four SAEs were reported (19%), leading to cessation of the biosimilar in 103 subjects (12.7%). Infusion reactions were 71, leading to cessation of the biosimilar in 53 subjects (6.5%), being significantly more frequent in patients pre-exposed to anti-TNFα (P = 0.017). The efficacy of therapy was calculated in 754 IBD patients, with a mean follow-up of 329 ± 202 days. Forty-eight patients had a primary failure (6.4%), and 188 (25.6%) lost response during follow-up. Six hundred twenty-eight (364 CD) and 360 IBD patients (222 CD) completed the follow-up at 6 and 12 months, respectively. At 12 months, patients without loss of response were 71%, 64%. and 82% in groups A, B, and C, respectively (log rank P = 0.01). Clinical/endoscopic scores and inflammatory biomarkers dropped significantly in CD and UC patients (P = 0.01 and P < 0.0001) compared with baseline. Conclusions: In this large prospective cohort, no further signals of difference in safety and effectiveness of CT-P13 in IBD has been observed.

Published
2019

14. Prospective observational study on inflammatory bowel disease patients treated with infliximab biosimilars: preliminary results of the PROSIT-BIO cohort of the IG-IBD

Author

Fiorino, G., Manetti, N., Variola, A., Bossa, F., Rizzuto, G., Guidi, L., Maconi, G., Ghione, S., Cantoro, L., Lorenzon, G., Fries, W., Annunziata, M. L., Costa, F., Terpin, M. M., Principi, B., Cortelezzi, C., Biancone, L., Amato, A., Occhipinti, P., Mazzuoli, S., Ardizzone, S., Di Girolamo, M., Alvisi, P., Meucci, G., Caserta, L., Saibeni, S., Petruzzellis, C., Ronchetti, A., Cappello, M., Castiglione, F., Danese, S., Massella, A., Varvara, D., Orlando, A., Armuzzi, A., Massari, A., Lionetti, P., Kohn, A., Renata D'Incà, Vecchi, M., Bertani, L., Annese, V., Fiorino, G, Manetti, N, Variola, A, Bossa, F, Rizzuto, G, Guidi, L, Maconi, G, Ghione, S, Cantoro, L, Lorenzon, G, Fries, W, Annunziata, Ml, Costa, F, Terpin, Mm, Principi, B, Cortelezzi, C, Biancone, L, Amato, A, Occhipinti, P, Mazzuoli, S, Ardizzone, S, Di Girolamo, M, Alvisi, P, Meucci, G, Caserta, L, Saibeni, S, Petruzzellis, C, Ronchetti, A, Cappello, M, Castiglione, F, Danese, S, Massella, A, Varvara, D, Orlando, A, Armuzzi, A, Massari, A, Lionetti, P, Kohn, A, D'Inca, R, Vecchi, M, Bertani, L, and Annese, V

Published
2016

15. The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilars

Author

Fiorino G, Manetti N, Variola A, Bossa F, Rizzuto G, Armuzzi A, Massari A, Ghione S, Cantoro L, Lorenzon G, Fries W, Annunziata ML, Costa F, Terpin MM, Principi M, Cortelezzi CC, Biancone L, Amato A, Occhipinti P, Mazzuoli S, Ardizzone S, Di Girolamo M, Alvisi P, Meucci G, Caserta L, Saibeni S, Petruzzzellis C, Ronchetti A, Cappello M, Castiglione F, Danese S, Massella A, Varvara D, Orlando A, Annese V, Fiorino, G, Manetti, N, Variola, A, Bossa, F, Rizzuto, G, Armuzzi, A, Massari, A, Ghione, S, Cantoro, L, Lorenzon, G, Fries, W, Annunziata, Ml, Costa, F, Terpin, Mm, Principi, M, Cortelezzi, Cc, Biancone, L, Amato, A, Occhipinti, P, Mazzuoli, S, Ardizzone, S, Di Girolamo, M, Alvisi, P, Meucci, G, Caserta, L, Saibeni, S, Petruzzzellis, C, Ronchetti, A, Cappello, M, Castiglione, F, Danese, S, Massella, A, Varvara, D, Orlando, A, and Annese, V

Published
2016

16. Thalidomide-induced peripheral neuropathy in children with inflammatory bowel disease

Author

Bramuzzo, M., Stocco, G., Montico, M., Arrigo, S., Calvi, A., Lanteri, P., Costa, S., Pellegrino, S., Magazzù, G., Berp, J., Ghione, S., Lionetti, P., Zuin, G., Fontana, M., Di Chio, T., Maggiore, Giuseppe, Lazzerini, M., Lucafò, M., Udina, C., Pellegrin, Mc, Chicco, A., Carrozzi, M., Decorti, G., Ventura, A., and Martellossi, S.

Subjects
NO
Published
2017

17. Strengths and limitations of current pediatric blood pressure nomograms: a global overview with a special emphasis on regional differences in neonates and infants

Author

Cantinotti M, Giordano R, Scalese M, Molinaro S, Murzi B, Assanta N, Crocetti M, Marotta M, Ghione S, Iervasi G, Cantinotti, M, Giordano, R, Scalese, M, Molinaro, S, Murzi, B, Assanta, N, Crocetti, M, Marotta, M, Ghione, S, and Iervasi, G

Abstract

The availability of robust nomograms is essential for the correct evaluation of blood pressure (BP) values in children. A literature search was conducted by accessing the National Library of Medicine by using the keywords BP, pediatric and reference values/nomograms. A total of 43 studies that evaluated pediatric BP nomograms were included in this review. Despite the accuracy of the latest studies, many numerical and methodological limitations still remain. The numerical limitations include the paucity of data for neonates/infants and for some geographic areas (Africa/South America/East Europe/Asia) and ethnicities. Furthermore, the data on ambulatory BP and response to exercise are extremely limited, and the criteria for stress-test interruption are lacking. There was heterogeneity in the methodologies employed to perform the measurements, in the inclusion/exclusion criteria (often not reported), in the data normalization and the data expression (Z-scores/percentiles/mean values). Although most studies adjusted the measurements for age and/or height, the classification by specific age/height subgroups varied. Gender differences were generally considered, whereas other confounders (that is, ethnicity/geographic area/environment) were seldom evaluated. As a result, nomograms were heterogeneous, and when comparable, at times showed widely different confidence intervals. These differences are most likely because of both methodological limitations and differences among the populations studied. Some robust nomograms exist (particularly those from the USA); however, it has been demonstrated that if adopted in other countries/continents, they may generate an unpredictable bias in the evaluation of BP values in children. Actual pediatric BP nomograms present consistent limitations that affect the evaluation of BP in children. Comprehensive nomograms, which are based on a large population of healthy children (including neonates/infants) and use standardized methodology, are warranted for every country/region.

Published
2015

18. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.

Author

Fiorino, G, Manetti, N, Armuzzi, Alessandro, Orlando, A, Variola, A, Bonovas, S, Bossa, F, Maconi, G, Dʼincà, R, Lionetti, P, Cantoro, L, Fries, W, Annunziata, Ml, Costa, F, Terpin, Mm, Biancone, L, Cortelezzi, Cc, Amato, A, Ardizzone, S, Danese, S, Guidi, Luisa, Rizzuto, G, Massella, A, Andriulli, A, Massari, A, Lorenzon, G, Ghione, S, Kohn, A, Ventra, A, Annese, V, Armuzzi A (ORCID:0000-0003-1572-0118), Guidi L (ORCID:0000-0003-3320-7094), Fiorino, G, Manetti, N, Armuzzi, Alessandro, Orlando, A, Variola, A, Bonovas, S, Bossa, F, Maconi, G, Dʼincà, R, Lionetti, P, Cantoro, L, Fries, W, Annunziata, Ml, Costa, F, Terpin, Mm, Biancone, L, Cortelezzi, Cc, Amato, A, Ardizzone, S, Danese, S, Guidi, Luisa, Rizzuto, G, Massella, A, Andriulli, A, Massari, A, Lorenzon, G, Ghione, S, Kohn, A, Ventra, A, Annese, V, Armuzzi A (ORCID:0000-0003-1572-0118), and Guidi L (ORCID:0000-0003-3320-7094)

Abstract

BACKGROUND: Few data are available on the safety and efficacy of infliximab biosimilar CT-P13 in patients with ulcerative colitis and Crohn's disease. METHODS: A prospective, multicenter, cohort study using a structured database. RESULTS: Consecutive patients (313 Crohn's disease and 234 ulcerative colitis) were enrolled from 31 referral centers; 311 patients were naive to anti-tumor necrosis factor alpha, 139 had a previous exposure to biologics, and the remaining 97 were switched to CT-P13 after a mean of 18 ± 14 infusions of infliximab. The mean follow-up was 4.3 ± 2.8 months, and the total follow-up time was 195 patient-years. After 2061 infusions, 66 serious adverse events were reported (12.1%), 38 (6.9%) of them were infusion-related reactions. The biosimilar had to be stopped in 29 (5.3%) cases for severe infusion reactions (8 naive, 19 previous exposed, and 2 switch), and in further 16 patients (2.9%) for other serious adverse events. Infusion reactions were significantly more frequent in patients pre-exposed to infliximab than to other anti-tumor necrosis factor alpha (incidence rate ratio = 2.82, 95% CI: 1.05-7.9). The efficacy of the biosimilar was evaluated in 434 patients who received treatment for at least 8 weeks, using time-to-event methods for censored observations: 35 patients were primary failures (8.1%). After further 8, 16, and 24 weeks, the efficacy estimations were 95.7%, 86.4%, and 73.7% for naive, 97.2%, 85.2%, and 62.2% for pre-exposed, and 94.5%, 90.8%, and 78.9% for switch, respectively (log-rank P = 0.64). CONCLUSIONS: Although no direct comparison was performed, preliminary data on efficacy and safety of CT-P13 were in line with those of infliximab.

Published
2017

25. Influencia del procesamiento del fruto de membrillo (Cydonia Oblonga Miller) en el contenido de polifenoles y actividad antioxidante del mismo

Author

Baroni, María Verónica, Gastaminza, J., Wunderlin, D., Rovasio, J.L., Dotti, R., Ghione, S., Ribotti, P., and Rosso, J.C.

Subjects
dulce, membrillo, capacidad antioxidante
Abstract

Los polifenoles son metabolitos secundarios presentes en gran proporción en las frutas, en su mayoría representados por los flavonoides y ácidos fenólicos. El creciente interés por estas sustancias es principalmente debido a su capacidad antioxidante y la asociación entre su consumo y la prevención de algunas enfermedades. Entre las frutas, el membrillo es una importante fuente de componentes que promueven la salud, tales como compuestos fenólicos. Si bien el membrillo no se consume fresco debido a su dureza, amargor y astringencia, es muy apreciado como materia prima para la producción de dulces y jaleas. El objetivo de este trabajo fue evaluar la propiedad antioxidante del fruto de membrillo, su dulce y los productos intermediarios de su elaboración, con el fin de estudiar el efecto del procesado térmico en las características nutricionales del mismo. Se analizaron el fruto (pulpa+piel), la mezcla cruda (pulpa+piel+azúcar) y el dulce regular y el reducido en carbohidratos. Se midió el contenido de polifenoles totales (PT), perfil de polifenoles por HPLC-DAD-MSMS y la actividad antioxidante in vitro por las técnicas DPPH (capacidad de atrapamiento de radicales libres) y FRAP (poder reductor). Todas las muestras analizadas presentaron un alto contenido de polifenoles en un rango de 200-500 mg ac. gálico/100g muestra (futo, mezcla cruda, dulce). Se demostró la actividad antioxidante in vitro por ambos métodos en todas las muestras. Los valores obtenidos variaron entre 400 y 1500 μmol TROLOX/100g muestra (futo, mezcla cruda, dulce). Tanto para la línea regular como la reducido en carbohidratos se mantuvo el contenido de polifenoles desde el fruto al dulce, conteniendo el regular 370 mg de ác. gálico/100 g de dulce y el light 184 mg ác. gálico/100g de dulce. Por otro lado se lograron identificar 16 compuestos polifenólicos, siendo los mayoritarios los ácidos cafeoil-quínicos, seguidos por los derivados del ácido cumárico, catequina y quercetina. La proporción de los distintos compuestos también se mantuvo desde el fruto al dulce, lo que significa que el procesado térmico no afecta cuantitativamente ni cualitativamente el contenido de polifenoles. Con respecto a la capacidad antioxidante determinada por DPPH y FRAP, como era de esperarse al mantenerse el contenido de polifenoles, no hubo tampoco pérdida de la actividad debido al procesamiento del membrillo. Los resultados obtenidos demuestran que el dulce de membrillo realiza un aporte importante de antioxidantes en la dieta, y además que no existe perdida en la calidad nutricional debido al procesado térmico. publishedVersion

Published
2014

26. Augmentation de l’incidence de la maladie de Crohn et de la rectocolite hémorragique chez l’adolescent sur une période de 21ans

Author

Ghione, S., primary, Michaud, L., additional, Sarter, H., additional, Armengol-Debeir, L., additional, Fumery, M., additional, Savoye, G., additional, Ley, D., additional, Spyckerelle, C., additional, Pariente, B., additional, Mouterde, O., additional, Djeddi, D., additional, Peyrin-Biroulet, L., additional, Gower, C., additional, and Turck, D., additional

Published
2016
Full Text
View/download PDF

27. La sindrome di Alagille

Author

Nastasio, S, Sciveres, M, Ghione, S, Marsalli, G, Cirillo, F, Riva, S, and Maggiore, Giuseppe

Subjects
Alagille syndrome, Chronic cholestasis, Notch pathway, Posterior embryotoxon, Pulmonary artery stenosis, Pediatrics, Perinatology and Child Health, Socio-culturale, Perinatology and Child Health, Pediatrics
Published
2013

32. PP.LB01.21

Author

Fommei, E., primary, Ghione, S., additional, Biagini, S., additional, Corrao, G., additional, and Mancia, G., additional

Published
2015
Full Text
View/download PDF

40. Colonoscopy practice in Italy: a prospective survey on behalf of the Italian Association of Hospital Gastroenterologists

Author

Radaelli, F, Meucci, G, Minoli, G, Italian Association of Hospital Gastroenterologists Alluminio, P, Amuso, M, Angelini, G, Anti, M, Baldi, F, Balzana, M, Barberani, F, Bargiggia, S, Barresi, G, Bedosti, M, Belmonte, A, Benedetti, A, Benedetti, E, Benini, M, Beretta, L, Beretta, P, Fontana, A, Mauro, B, Bianco, R, Bierti, L, Bigazzi, U, Boccia, S, Bonello, F, Boscarino, S, Bottini, E, Bresci, G, Briglia, U, Brunelli, E, Buggiani, D, Calandra, A, Candidi, A, Caneschi, F, Cannizzaro, R, Cappuccino, V, Caputi, O, Cardelli, A, Caronia, V, Cattuto, C, Cestari, E, Chilovi, F, Cifatte, D, Ciliberto, E, Cimino, F, Cipolletta, V, Cirillo, M, Cocozza, U, Colantuoni, E, Coli, A, Colombo, E, Comin, U, Conti, W, Cortini, C, Criscione, S, Crotta, S, Cutela, P, D'Imperio, N, Dalia, G, Dall'Oglio, L, Dal Pane, M, Dante, P, Dato, D, Dattola, L, De Bernardin, M, De Boni, M, De Conca, V, Dell'Amico, I, Dell'Anna, A, Della Spoletina, A, Delogu, G, Del Piano, M, Di Cicco, M, Di Filippo, G, Di Giorgio, P, Di Mitri, R, Di Piero, A, Di Piramo, D, Di Todaro, E, Dicillo, M, Dodero, C, Doldo, P, Drago, D, Dubla, G, Dughera, L, Dusio, P, Ederle, A, Evola, M, Fachinetti, F, Faraldo, G, Farroni, F, Fasoli, R, Ferrara, A, Ferrari, A, Ferrari, C, Ferraris, L, Ferraris, R, Ferrini, G, Ferrini, L, Foco, A, Forte, G, Francavilla, A, Franzè, A, Fregoni, D, Frieri, Giuseppe, Gaia, E, Galasso, F, Galgani, P, Gamberucci, G, Gatti, L, Gatti, M, Gemme, C, Ghione, S, Ghisotti, E, Giaccari, S, Giannelli, C, Giorcelli, V, Giuri, G, Giurissa, A, Grassini, M, Grasso, G, Graziani, Mg, Gualtiero, J, Gullini, S, Gullotta, R, Iaquinto, G, Jacoponi, S, Laganà, S, Lamanda, R, Lattanzio, R, Lauri, A, Lecis, Pe, Ledda, P, Leone, S, Ligas, E, Liuzzi, N, Lochis, D, Longaroni, M, Lorenzini, I, Loriga, P, Lussu, B, Luzza, F, Madia, D, Malfitana, G, Mallozzi, Ef, Mancini, S, Mangiarotti, R, Manildo, M, Manneschi, L, Marcon, V, Marino, M, Marrucci, A, Martines, H, Maruelli, A, Massari, M, Massidda, C, Mauri, R, Mazzarello, Pl, Mazzolla, E, Mellone, C, Meloni, M, Merighi, A, Mescia, P, Michetti, P, Milan, L, Milandri, G, Miori, G, Monastra, S, Moncelli, G, Monica, F, Montanaro, F, Moretti, M, Morini, S, Mosca, F, Mosca, D, Moschetta, R, Mura, G, Naim, G, Nardella, G, Natale, A, Negrini, F, Niccoli, G, Nova, A, Occhipinti, P, Ocera, S, Orlandi, Pg, Orsini, O, Pagani, E, Paliani, O, Pardocchi, D, Parodi, Cm, Pasini, D, Pasquale, L, Pasquali, L, Paterlini, A, Pellecchia, A, Pera, A, Perego, M, Perugini, B, Petracca, F, Peyre, S, Piccoli, F, Pilati, S, Pierucci, E, Pizzetti, P, Pizzolato, S, Polimeni, F, Politano, S, Polo, S, Portaluri, F, Prada, A, Privitera, U, Quaranta, S, Raguzzi, I, Ravelli, P, Recchia, S, Revetria, P, Ripoli, D, Rocca, F, Roda, E, Rogheto, M, Rosati, S, Rosina, F, Rossi, A, Rotolo, A, Sabadini, Gr, Saffiotti, O, Salerno, D, Sanesi, A, Sanna, S, Saracco, G, Savarino, V, Scaccianoce, G, Scarpulla, G, Schiffino, L, Schippa, P, Sebastiani, P, Servillo, F, Sgarbi, D, Sigillito, D, Snider, L, Sorrentini, I, Spadaccini, A, Sticchi, V, Sturniolo, Gc, Suriani, R, Tammaro, L, Tarchi, F, Tasini, E, Tebaldi, M, Terruzzi, V, Testoni, Pa, Tonelli, F, Trapè, R, Triossi, O, Usai, P, Usula, E, Vecchi, M, Vecchi, E, Ventrucci, M, Viero, K, Virgilio, C, Viviani, G, Zampaletta, U, and Zilli, M.

Subjects
Colonoscopy, Endoscopy
Published
2008

Catalog

Books, media, physical & digital resources
See catalog results